STOCK TITAN
  1. Home
  2. Sec-filings
  3. WST
  4. [Form 4] WEST PHARMACEUTICAL SERVICES INC Insider Trading Activity

West Pharmaceutical (WST) director granted 791 restricted stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LAI GOLDMAN MYLA reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services director Myla Lai-Goldman received 791 shares of Common Stock as a grant. The award was made at no cash cost per share and increased her directly held position to 20,434.587 shares.

According to the footnote, these shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors.

Positive

  • None.

Negative

  • None.
Insider LAI GOLDMAN MYLA
Role null
Type Security Shares Price Value
Grant/Award Common Stock 791 $0.00 --
Holdings After Transaction: Common Stock — 20,434.587 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares granted 791 shares Restricted stock unit award on May 4, 2026
Grant price $0.0000 per share Stated transaction price for award
Shares after transaction 20,434.587 shares Direct holdings following the grant
restricted stock units financial
"These shares of restricted stock units will vest in full on the date"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Deferred Compensation Plan for Outside Directors financial
"will be distributable under the terms of the Deferred Compensation Plan for Outside Directors"
annual shareholder meeting financial
"will vest in full on the date of the next annual shareholder meeting"
A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAI GOLDMAN MYLA
(Last)(First)(Middle)
530 HERMAN O. WEST DRIVE
(Street)
EXTON PENNSYLVANIA 19341
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/04/2026A791(1)A$020,434.587D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
/s/ Louis Lalli, as an agent for Myla Lai Goldman05/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did director Myla Lai-Goldman report in this West Pharmaceutical (WST) Form 4?

Director Myla Lai-Goldman reported receiving 791 shares of West Pharmaceutical Common Stock as a grant. This award is part of her director compensation and increased her direct holdings to 20,434.587 shares following the transaction on May 4, 2026.

Was Myla Lai-Goldman’s West Pharmaceutical (WST) transaction a market purchase or sale?

The transaction was a grant or award acquisition, not a market purchase or sale. She received 791 shares at a stated price of $0.0000 per share as compensation, rather than buying or selling shares in the open market.

How many West Pharmaceutical (WST) shares does Myla Lai-Goldman hold after this grant?

After the award of 791 shares, Myla Lai-Goldman directly holds 20,434.587 shares of West Pharmaceutical Common Stock. This total reflects her position immediately following the reported Form 4 transaction dated May 4, 2026.

What are the vesting terms of Myla Lai-Goldman’s West Pharmaceutical restricted stock units?

The 791 shares are restricted stock units that will vest in full on the date of the next annual shareholder meeting. Once vested, they will be distributed under West Pharmaceutical’s Deferred Compensation Plan for Outside Directors in accordance with that plan’s terms.

Does the West Pharmaceutical (WST) Form 4 mention any derivative securities or option exercises?

The Form 4 data show no derivative security transactions or option exercises for this event. The filing only reports a non-derivative acquisition of 791 shares of Common Stock as a grant, with no remaining derivative positions listed in the derivative summary.